期刊文献+

牛磺酸联合水飞蓟宾治疗非酒精性脂肪性肝炎100例 被引量:3

Therapeutic Effects of Taurine Combined with Silibinin in 100 Patients with Non-alcoholic Steatohepatitis
原文传递
导出
摘要 目的评价牛磺酸联合水飞蓟宾治疗非酒精性脂肪性肝炎(NASH)的疗效。方法将200例NASH患者随机分为治疗组(100例)和对照组(100例)。治疗组采用牛磺酸联合水飞蓟宾治疗,对照纽单用牛磺酸治疗,疗程均为24周。所有患者均禁酒,改善饮食结构,进行中等量有氧运动,控制体重。观察患者治疗前后临床症状、血压、体质量指数(BMl)和腰围变化,检测患者治疗前后肝功能、血脂、空腹血糖水平,并行B超和CT检查。结果治疗后两组临床症状及相关化验检查明显改善,B超和CT提示脂肪肝程度减轻(P<0.05):其中乏力、肝区不适、恶心、呕吐症状改善情况,收缩压、舒张压、BMI、ALT、GGT、三酰甘油、总胆固醇下降程度,B超和CT提示脂肪肝减轻程度等治疗组优于对照组(P<0.05)。对照组女性、治疗组男性和女性治疗后腰围较治疗前明显减小(P<0.05)。结论牛磺酸对NASH患者有明显的疗效,牛磺酸联合水飞蓟宾治疗NASH患者疗效优于单用牛磺酸患者。 Objective To evaluate the therapeutic effects of taurine combined with silibinin in patients with non-alcoholic steatohepatitis(NASH). Methods 200 cases of NASH patients were randomly divided in the treatment group ( 100 cases) and the control group (100 cases). Patients in the treatment group received taurine combined with silibinin for 24 weeks, and patients in thecontrol group received silibinin for 24 weeks. All patients were recommended to abstain from alcohol, improve dining structure, take moderate aerobic exercises, and keep body weight. Clinical symptoms, blood pressures, body mass indexes (BMI) and waist circumferences were observed before and after treatment in all patients ;liver functions, blood lipid and fasting glucose levels were tested, type-B ultrasonic and CT images were evaluated before and after treatment in all panents. Results After treatment,the significant improvement of clinical symptoms and laboratory tests ; type- B ultrasonic and CT examination showed that steatohepatitits were ameliorated in both groups ( P 〈 0.05 ). Therapeutic effects in the treatment group were superior to those in the control group in aspect of symptoms amelioration including asthenia, liver area discomfort, nausea and vomiting, decrease of systolic and diastolic blood pressure, BMI, serum ALT, GGT, triglyceride and cholesterol levels ; in addition, ultrasonic or CT examination showed that extents of steatohepatitits amelioration were better in the treatment group ( P 〈 0.05 ).Waist circumferences reduced significantly after treatment in women in the control group, men and women in the treatment group (P 〈 0.05 ). Conclusion Taurine is effective in patients with NASH, and combination of taurine and silibiniu has superior treatment efficacy compared with taurine alone in patients with NASH.
出处 《临床消化病杂志》 2013年第3期176-178,共3页 Chinese Journal of Clinical Gastroenterology
关键词 非酒精性脂肪性肝炎 牛磺酸 水飞蓟宾 Non- alcoholic steatohepatitis Taurine Silibinin
  • 相关文献

参考文献5

二级参考文献39

  • 1Fan, Jian-Gao,Peng, Yong-De.Metabolic syndrome and non-alcoholic fatty liver disease:Asian definitions and Asian studies[J].Hepatobiliary & Pancreatic Diseases International,2007,6(6):572-578. 被引量:42
  • 2项坤三.临床糖尿病本质认识的深化[J].中华糖尿病杂志,2009,1(1). 被引量:11
  • 3范建高.糖尿病与肝病的关系及其诊治对策[J].中华糖尿病杂志,2009,1(4). 被引量:30
  • 4陈岳祥,刘苏,曾欣,谢渭芬.牛磺酸治疗非酒精性脂肪肝19例临床观察[J].中国实用内科杂志,2005,25(3):249-250. 被引量:14
  • 5ZHENG L, LV G C, SHENG J, et al. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD [ J ]. J Gastroenterol Hepatol, 2010, 25 (1) : 156-163.
  • 6ARGO C K, CALDWELL S H. Epidemiology and natural history of non-alcoholic steatohepatitis[J]. Clin Liver Dis, 2009, 13 (4) : 511-531.
  • 7PEITA S, MURATORE C, CRAXI A. Non-alcoholic fatty liver disease pathogenesis: the present and the future[J]. Dig Liver Dis, 2009, 41 (9) : 615-625.
  • 8BEGRICHE K, IGOUDJIL A, PESSAYRE D, et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it[ J]. Mitochondrion, 2006, 6 ( 1 ) : 1-28.
  • 9FRAULOB J C, OGG-DIAMANTINO R, FERNANDESSANTOS C, et al. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet [ J]. J Clin Biochem Nutr, 2010, 46 (3) : 212-223.
  • 10CHEN S, LI Y, LI S, et al. A Va1227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio [ J ]. J Gastroenterol Hepatol, 2008, 23 (9): 1415-1418.

共引文献1218

同被引文献50

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部